A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib

Detalles Bibliográficos
Autores principales: Clark, Mary, Imbriano, Paul, Harwood, Michael, Busam, Klaus, Robinson-Bostom, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098385/
https://www.ncbi.nlm.nih.gov/pubmed/35572199
http://dx.doi.org/10.1016/j.jdcr.2022.03.006
_version_ 1784706371457908736
author Clark, Mary
Imbriano, Paul
Harwood, Michael
Busam, Klaus
Robinson-Bostom, Leslie
author_facet Clark, Mary
Imbriano, Paul
Harwood, Michael
Busam, Klaus
Robinson-Bostom, Leslie
author_sort Clark, Mary
collection PubMed
description
format Online
Article
Text
id pubmed-9098385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90983852022-05-14 A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib Clark, Mary Imbriano, Paul Harwood, Michael Busam, Klaus Robinson-Bostom, Leslie JAAD Case Rep Case Report Elsevier 2022-04-01 /pmc/articles/PMC9098385/ /pubmed/35572199 http://dx.doi.org/10.1016/j.jdcr.2022.03.006 Text en © 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Clark, Mary
Imbriano, Paul
Harwood, Michael
Busam, Klaus
Robinson-Bostom, Leslie
A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title_full A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title_fullStr A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title_full_unstemmed A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title_short A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
title_sort diagnostic dilemma: atypical melanocytic lesions arising in the setting of treatment with the braf inhibitor, vemurafenib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098385/
https://www.ncbi.nlm.nih.gov/pubmed/35572199
http://dx.doi.org/10.1016/j.jdcr.2022.03.006
work_keys_str_mv AT clarkmary adiagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT imbrianopaul adiagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT harwoodmichael adiagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT busamklaus adiagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT robinsonbostomleslie adiagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT clarkmary diagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT imbrianopaul diagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT harwoodmichael diagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT busamklaus diagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib
AT robinsonbostomleslie diagnosticdilemmaatypicalmelanocyticlesionsarisinginthesettingoftreatmentwiththebrafinhibitorvemurafenib

Ejemplares similares